Efficacy and Safety of Rivaroxaban Versus Warfarin in P Nondihydropyridine Calcium Channel Blockers for Atri AF Trial)

American Journal of Cardiology

120, 588-594

DOI: 10.1016/j.amjcard.2017.05.026

Citation Report

#	Article	IF	Citations
1	Rivaroxaban Plasma Levels in Patients Admitted for Bleeding Events: Insights From a Prospective Study. Thrombosis Journal, 2018, 16, 1-8.	2.9	78
2	Drug-Drug Interactions in an Era of Multiple Anticoagulants: A Focus on Clinically Relevant Drug Interactions. Blood, 2018, 132, 2230-2239.	10.6	78
3	American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Optimal Management of Anticoagulation Therapy. Blood Advances, 2018, 2, 3257-3291.	6.3	476
4	Drug-Drug Interactions in an Era of Multiple Anticoagulants: A Focus on Clinically Relevant Drug Interactions. Hematology, 2018, 2018, 339-347.	2.5	44
5	Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. Annals of Pharmacotherapy, 2019, 53, 21-27.	2.9	27
6	Indications and Potential Pitfalls of Anticoagulants in Pulmonary Hypertension: Would DOACs Become a Better Option Than VKAs?. Blood Reviews, 2019, 37, 100579.	7.6	23
7	Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics, 2019, 11, 133.	7.5	23
8	Sex Differences in Rate and Rhythm Control for Atrial Fibrillation. Europace, 2019, 21, 690-697.	8.4	33
9	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e679.	1.1	4
10	Drug-Drug Interactions With Direct Oral Anticoagulants Associated With Adverse Events in the Real World: A Systematic Review. Thrombosis Research, 2020, 194, 240-245.	2.9	77
11	The Increased Risk of Bleeding Due to Drug-Drug Interactions in Patients Administered Direct Oral Anticoagulants. Thrombosis Research, 2020, 195, 243-249.	2.9	42
12	The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. Clinical Pharmacology and Therapeutics, 2020, 107, 1446-1456.	5.3	7
13	The Real World Use of Combined P-Glycoprotein and Moderate CYP3A4 Inhibitors With Rivaroxaban or Apixaban Increases Bleeding. Journal of Thrombosis and Thrombolysis, 2020, 49, 636-643.	2.2	91
14	Drug-Drug Interactions Leading to Adverse Drug Reactions With Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. Journal of Personalized Medicine, 2021, 11, 250.	3.9	19
15	Update on Drug Interactions With Non-Vitamin-K-Antagonist Oral Anticoagulants for Stroke Prevention in Elderly Patients. Expert Review of Clinical Pharmacology, 2021, 14, 569-581.	3.6	8
16	Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients With Hypertension and Atrial Fibrillation: A Meta-Analysis. Cardiovascular Therapeutics, 2021, 2021, 6628469.	3.0	14
17	Prevalence, Management and Impact of Chronic Obstructive Pulmonary Disease in Atrial Fibrillation: A Systematic Review and Meta-Analysis of 4,200,000 Patients. European Heart Journal, 2021, 42, 3541-3554.	14.7	82
18	Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1526-1536.	5.3	99

#	Article	IF	Citations
19	A Comprehensive Care Plan That Reduces Readmissions After Acute Exacerbations of COPD. Respiratory Medicine, 2018, 141, 20-25.	3.5	20
20	Drug-Drug Interaction of Rivaroxaban and Calcium Channel Blockers in Patients Aged 80 Years and Older With Nonvalvular Atrial Fibrillation. Drug Metabolism and Personalized Therapy, 2020, .	1.7	5
21	Analysis of bioMARKer Distribution and Individual Reproducibility Under Rivaroxaban Treatment in Japanese Patients With Non-Valvular Atrial Fibrillation (R-MARK Study, CVI ARO2). International Heart Journal, 2020, 61, 695-704.	1.4	3
22	Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients With Atrial Fibrillation Using P-Gp And/Or CYP450-Interacting Drugs: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2023, 37, 781-791.	4.1	16
23	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. CJC Open, 2022, 4, 315-323.	1.8	24
24	Impact of P-Glycoprotein And/Or CYP3A4-Interacting Drugs on Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. British Journal of Clinical Pharmacology, 2022, 88, 3039-3051.	3.0	25
25	Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants. Journal of Pharmacy Practice, 2023, 36, 600-605.	1.3	4
26	Drug–Drug Interaction of Rivaroxaban and Calcium Channel Blockers in Patients Aged 80 Years and Older With Nonvalvular Atrial Fibrillation. Drug Metabolism and Personalized Therapy, 2020, .	1.7	11
27	Evaluating Pharmacokinetic Drug–Drug Interactions of Direct Oral Anticoagulants in Patients With Renal Dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 189-202.	4.8	6
28	Drug Interactions Affecting Oral Anticoagulant Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, e007956.	6.8	106
29	Screening the Influence of Diltiazem on Oral Antidiabetic Agents in Experimental Animals. Indian Drugs, 2022, 59, 54-61.	0.4	1
30	Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e025723.	5.8	23
31	DOAC Drug Interactions Management Resource. Canadian Pharmacists Journal, 2022, 155, 315-325.	1.8	7
32	2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension, 2023, 41, 1874.	3.0	3,493
33	Prevalence and Bleeding Risk Associated With the Concomitant Use of Direct Oral Anticoagulants and Antiarrhythmic Drugs in Patients With Atrial Fibrillation, Based on the French Healthcare Insurance Database. European Journal of Clinical Pharmacology, 2023, 79, 937-945.	3.8	6
34	Safety of Direct Oral Anticoagulant Use in Patients Taking Verapamil or Diltiazem. Heart Rhythm, 2023, 20, 1793-1795.	3.8	5
35	Impact of P-Glycoprotein and CYP3A4-Interacting Drugs on Clinical Outcomes in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 722-730.	5.0	52
36	Calcium Channel Blockers and Clinical Outcomes in Patients With Continuous-Flow Left Ventricular Assist Devices. ESC Heart Failure, 2024, 11, 271-281.	4.1	2

#	Article	IF	Citations
37	Effectiveness and Safety of Different Oral Anticoagulants With P-Glycoprotein/ CYP3A4 Inhibitors: A Network Meta-Analysis. Current Pharmaceutical Design, 2024, 30, 1167-1177.	3.4	1
38	Potential Interactions Between Medications for Rate Control and Direct Oral Anticoagulants: Population-Based Cohort and Case-Crossover Study. Heart Rhythm, 2024, 0, 2445-2454.	3.8	5
39	Diltiazem, Direct Oral Anticoagulants, and Risk of Major Bleeding in Patients With Atrial Fibrillation. Heart Rhythm, 2024, 0, 2455-2457.	3.8	1
40	Tailoring Oral Anticoagulant Treatment in the Era of Multi-Drug Therapies for PAH and CTEPH. Blood Reviews, 2024, 68, 101240.	7.6	6
41	Construction of Cytochrome P450 3A and P-Glycoprotein Knockout Rats With Application in Rivaroxaban-Verapamil Interactions. Biochemical Pharmacology, 2024, 230, 116566.	6.7	3
42	Клинические рекомендации Российского медицинского общества по артериальной гипертонии (РМОАГ) и Евразийской Ассоциации Кардиологов (ЕАК) по диагностике и лечению артериальной гипертонии (2024). Systemic Hypertension, 2024, 21, 5-110.	0.9	22
43	Impact of Cytochrome P-450 3A4 Enzyme/P-Glycoprotein Inducing Antiseizure Medications on Direct Oral Anticoagulant Therapy. Blood Coagulation and Fibrinolysis, 2025, 36, 10.1097/MBC.0000000000001342.	1.0	4
44	Bleeding Risk Associated With the Co-Use of Direct Oral Anticoagulants and Non-Dihydropyridine Calcium Channel Blockers: A Meta-Analysis. Herz, 2026, 51, 1-6.	1.8	0